Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
Year: 2018
Type: article
Study design: Clinical Trial
Source: Clinical Colorectal Cancer
Authors: Jeremy D. Shapiro, Subotheni Thavaneswaran, Craig R. Underhill, Kristy P. Robledo, Christos S. Karapetis, Fiona L. Day, Louise M. Nott, Michael Jefford, Lorraine A. Chantrill, Nick Pavlakis, Niall C. Tebbutt, Timothy. J. Price, Mustafa Khasraw, Guy A. Van Hazel, Paul M. Waring, Sabine Tejpar, John Simes, Val J. Gebski, Jayesh Desai, Eva Segelov
Institutions: Cabrini Hospital, Monash University, The University of Sydney, National Health and Medical Research Council, UNSW Sydney, Flinders University, Flinders Medical Centre, Calvary Mater Newcastle Hospital, University of Newcastle Australia, Royal Hobart Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Sydney, The Kinghorn Cancer Centre, Royal North Shore Hospital, Northern Cancer Institute, Austin Hospital, Austin Health, Lyell McEwin Hospital, Geelong Hospital, The University of Western Australia, Universitair Ziekenhuis Leuven, The Royal Melbourne Hospital, Monash Health
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2806803918